BeOne Medicines Ltd. (stock code 06160) reported no changes to its authorised, registered or issued share capital for June 2026, while expanding the pool of employee equity incentives and confirming continued compliance with Hong Kong’s 25% public-float requirement.
Authorised and Issued Share Capital • Authorised/registered share capital remained at 2.31 billion ordinary shares with a par value of USD 0.0001, equivalent to USD 0.23 million. • Issued share count (excluding treasury shares) was unchanged at 1.43 billion shares. The company holds no treasury shares.
Public Float • The company affirmed that its free float meets the Main Board’s Initial Prescribed Threshold of 25% of issued shares.
Non-HK-listed Shares • BeOne maintains 115.06 million RMB-denominated shares listed on Shanghai’s STAR Market (stock code 688235). These shares are not fungible with the Hong Kong-listed ordinary shares.
Equity Incentive Activity • Under the Fifth Amended and Restated 2016 Share Option and Incentive Plan, 23.36 million options were granted and 1.06 million were cancelled, lifting outstanding options to 51.51 million. • The Sixth Amended and Restated 2018 Employee Share Purchase Plan can issue up to 5.69 million shares. • Total funds received from option exercises during the month were USD 0.81 million, though no additional shares were issued in June. • Outstanding awards include performance share units recorded at 100% target vesting; actual vesting may reach up to 200% after the three-year performance period.
Equity Award Reserve • Of the 133.00 million shares originally held by subsidiary BG NC 2, Ltd. for equity-award settlements, 61.47 million have been issued to grantees as of 30 June 2026. The remaining shares are not yet considered outstanding under Swiss law and carry no current dilutive effect.
Capital Band Flexibility • The board retains authority, under Swiss law and the Articles of Association adopted on 28 April 2025, to adjust share capital within a band of USD 138,687.83 to USD 231,146.38 until 28 April 2029.
Governance and Compliance • All securities transactions during the month were duly authorised by the board and executed in accordance with Hong Kong Listing Rules and applicable laws, as confirmed by Executive Director, Chairman and CEO John V. Oyler on 8 July 2026.
With a stable share base, a confirmed public float above regulatory thresholds, and an expanded option pool to support talent retention, BeOne Medicines enters the second half of 2026 with solid capital flexibility and compliant governance structures.
Comments